Código QR (código de barras bidimensional)

Safety of Lorlatinib in Patients with Unresectable Advanced <i>ALK</i>-Positive Non-Small-Cell Lung Cancer Previously Treated with ALK Inhibitors: A Single-Arm, Open-Label, Phase IV Study in India

Lorlatinib is approved in India for patients with previously treated anaplastic lymphoma kinase (ALK)–positive advanced or recurrent non-small-cell lung cancer (NSCLC). Owing to the limited number of Indian patients in phase I/II and III studies, a postapproval study was conducted to report the safe...

Fuld beskrivelse

Na minha lista:
Principais autores: Ullas Batra, Vineet G. Gupta, Nirmal Raut, Tushar Patil, Harsha Panchal, Nikhil Ghadyalpatil, Anand Pathak, Chirag Desai, Shailesh Bondarde, Minish Jain, Christian Russel Reyes, Shyam Parvatini, Seema Pai, Francesca Toffalorio, Holger Thurm, Bivas Biswas
Format: Artigo
Sprog:Inglês
Udgivet: Thieme Medical and Scientific Publishers Pvt. Ltd. 2025-08-01
Serier:Indian Journal of Medical and Paediatric Oncology
Fag:
ALK tyrosine kinase inhibitor
lorlatinib
non-small-cell lung cancer
safety
Online adgang:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1801883
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker